Abstract
Subacute cutaneous lupus erythematosus (SCLE) is a common manifestation of systemic lupus erythematosus. In many cases it appears to be resistant to various systemic or topical treatments. Three cases of resistant SCLE with good response to intravenous immunoglobulin (IVIG) are described here suggesting that IVIG could be an alternative treatment in these patients.
References
Sontheimer RD (2005) Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological and genetic findings. Autoimmun Rev 4:253–263
Parodi A, Caproni M, Cardinali C, Bernacchi E, Fuligni A, De Panfilis G et al (2000) Clinical, histological and immunopathological features of 58 patients with subacute cutaneous lupus erythematosus. A review by the Italian group of immunodermatology. Dermatology 200:6–10
Dalakas MC (1998) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51:S2–S8
Toubi E, Kessel A, Shoenfeld Y (2005) High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 66:395–402
Stangel M, Gold R (2005) Intravenous immunoglobulins in MS. Int MS J 12:5–10
Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G (2004) Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann Rheum Dis 63:1649–1654
D’ Cruz DP, Hughes GR (2005) The treatment of lupus nephritis. BMJ 330:377–378
Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367–2377
Shoenfeld Y, Katz U (2005) IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 38:123–137
Whitington PF, Hibbard JU (2004) High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis. Lancet 364:1690–1698
Mosca M, Strigini F, Carmignani A, D’ Ascanio A, Genazzani AR, Bombardieri S (2005) Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy. Arthritis Rheum 53:119–121
Ruetter A, Luger TA (2004) Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol 5:153–160
Goodfield M, Davison K, Bowden K (2004) Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 15:46–50
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lampropoulos, C.E., Hughes, G.R.V. & Cruz, D.P.D. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol 26, 981–983 (2007). https://doi.org/10.1007/s10067-006-0222-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0222-5